TD Cowen on Black Diamond Therapeutics (BDTX) Amid 18% Drop: 'is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead'
Tweet Send to a Friend
TD Cowen analyst Marc Frahm reiterated a Buy rating and {REMOVEPT} price target on Black Diamond Therapeutics (NASDAQ: BDTX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
